Yazar "Cihan, Şener" için listeleme
-
The clinical and pathologic characteristics of 400 gastrointestinal stroinal tumor patients from Turkey: The final results of the Turkish Anatolian Society of Medical Oncology Multicenter Registery
Sevinç, Alper; Şeker, Mesut; Yıldız, Ramazan; Cihan, Şener; Kaplan, Mehmet Ali; Dane, Faysal; Karaca, Halit; Üyetürk, Ümmügül; Bilici, Ahmet; Özdemir, Nuriye; Uncu, Doğan; Salepçi, Tafian; Işıkdoğan, Abdurrahman; Benekli, Mustafa; Özkan, Metin; Gümüş, Mahmut; Öksüzoğlu, Berna (American Society of Clinical Oncology, 2014)… -
The conversion ofRASstatus in metastatic colorectal cancer patients after first-line biological agent treatment
Arıcı, Serdar; Hamdard, Jamshid; Sakin, Abdullah; Şengiz Erhan, Selma; Atçı, Muhammed Mustafa; Cekin, Ruhper; Saka, Burcu; Köse, Emin; Saydam, Tuba; Geredeli, Çağlayan; Cihan, Şener; Bilici, Ahmet (Wiley, 2021)Aim The aim was to investigate theRASdiscordance between initial and recurrent metastasectomy specimens in metastatic colorectal cancer (mCRC) patients treated with chemotherapy (CT) plus biological agents in a first-line ... -
Medication errors in chemotherapy preparation and administration: A survey conducted among oncology nurses in Turkey
Ulaş, Arife; Sılay, Kamile; Akıncı, Sema; Dede, Didem Şener; Akıncı, Muhammed Bülent; Şendur, Mehmet Ali; Çubukçu, Erdem; Çoşkun, Hasan Şenol; Deǧirmenci, Mustafa; Utkan, Güngör Ör; Özdemir, Nuriye Yıldırım; Işıkdoğan, Abdurrahman; Büyükçeli̇k, Abdullah; İnanç, Mevlüde; Bilici, Ahmet Erkan; Odabaşı, Hatice; Cihan, Şener; Avcı, Nilüfer; Yalçın, Bülent (Asian Pacific Organization for Cancer Prevention, 2015)Background: Medication errors in oncology may cause severe clinical problems due to low therapeutic indices and high toxicity of chemotherapeutic agents. We aimed to investigate unintentional medication errors and underlying ... -
Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors
Gümüş, Mahmut; Bilici, Ahmet; Odabaş, Hatice; Öven Ustaalioğlu, Bala Başak; Kandemir, Nurten; Demirci, Umut; Cihan, Şener; Bayoğlu, İbrahim Vedat; Öztürk, Türkan; Türkmen, Esma; Urakçı, Zürat; Şeker, Mehmet Metin; Günaydın, Yusuf; Selçukbiricik, Fatih; Turan, Nedim; Sevinç, Alper (Springer, 2017)Background Currently, it is accepted that risk assessment of clinical stage I (CS I) nonseminomatous germ cell tumors (NSGCT) patient is mainly dependent on the presence of lymphovascular invasion (LVI). Initial active ... -
Outcomes of surveillance VS. adjuvant chemotherapy for patients with STAGE IA and IB NON-seminomatous testicular germ-cell tumors
Bilici, Ahmet; Gümüş, Mahmut; Odabaş, Hatice; Kandemir, Nurten; Demirci, Umut; Cihan, Şener; Bayoğlu, İbrahim Vedat; Öven Ustaalıoğlu, Bala Başak; Öztürk, Türkan; Türkmen, Esma; Urakçı, Zuhat; Şeker, Mehmet Metin; Günaydın, Yusuf; Selçukbiricik, Fatih; Turan, Nedim; Sevinç, Alper (American Society of Clinical Oncology, 2016)... -
Treatment preferences in stage IA and IB testicular seminoma: Multicenter study of anatolian society of medical oncology
Bilici, Ahmet; Öztürk, Türkan; Türkmen, Esma; Odabaş, Hatice; Cihan, Şener; Selçukbiricik, Fatih; Erdoğan, Bülent; Urakçı, Zuhat; Kandemir, Nurten; Bayoğu, İbrahim Vedat; Demirci, Umut; Ocak Duran, Ayşe; Şendur, Mehmet Ali; Yavuzer, Dilek; Harputluoğlu, Hakan; Kavgacı, Halil; Gümüş, Mahmut (Springer, 2015)Approximately 75 % of patients with testicular seminoma present with stage I disease, and the probability of long-term survival approaches 100 %. However, the standard adjuvant treatment for stage I seminoma patients remains ...